Literature DB >> 10859525

Bronchus-associated lymphoid tissue (BALT) is not present in the normal adult lung but in different diseases.

T Tschernig1, R Pabst.   

Abstract

Bronchus-associated lymphoid tissue (BALT) was first described in the lungs of rabbits and differs greatly between species. It is part of the integrated mucosal immune system. This review clarifies its morphological definition and focuses on the situation in humans. The frequency of BALT at different ages, after chronic stimulation and in different diseases is described. In healthy humans, BALT can only be found in the lungs of children and adolescents. The role of BALT in lung transplantation and in the development of low-grade malignant lymphomas in the airways is also discussed. Furthermore, questions concerning the inducibility of BALT as an entry site for vaccines, and the regulation of its activity for future therapeutic interventions in pulmonary immune reactions are addressed. Copyright 2000 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2000        PMID: 10859525     DOI: 10.1159/000028109

Source DB:  PubMed          Journal:  Pathobiology        ISSN: 1015-2008            Impact factor:   4.342


  67 in total

Review 1.  The impact of perinatal immune development on mucosal homeostasis and chronic inflammation.

Authors:  Harald Renz; Per Brandtzaeg; Mathias Hornef
Journal:  Nat Rev Immunol       Date:  2011-12-09       Impact factor: 53.106

2.  Role of lymphotoxin and homeostatic chemokines in the development and function of local lymphoid tissues in the respiratory tract.

Authors:  Javier Rangel-Moreno; Damian Carragher; Troy D Randall
Journal:  Inmunologia       Date:  2007

3.  Imbalance of apoptosis and cell proliferation contributes to the development and persistence of emphysema.

Authors:  Ji-Hyun Lee; Masayuki Hanaoka; Yoshiaki Kitaguchi; Donatas Kraskauskas; Leland Shapiro; Norbert F Voelkel; Laima Taraseviciene-Stewart
Journal:  Lung       Date:  2011-10-21       Impact factor: 2.584

Review 4.  Mucosal vaccines: novel strategies and applications for the control of pathogens and tumors at mucosal sites.

Authors:  Mevyn Nizard; Mariana O Diniz; Helene Roussel; Thi Tran; Luis Cs Ferreira; Cecile Badoual; Eric Tartour
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

5.  Lymphoid follicle cells in chronic obstructive pulmonary disease overexpress the chemokine receptor CXCR3.

Authors:  Steven G Kelsen; Mark O Aksoy; Mary Georgy; Richard Hershman; Rong Ji; Xiuxia Li; Matthew Hurford; Charalambos Solomides; Wissam Chatila; Victor Kim
Journal:  Am J Respir Crit Care Med       Date:  2009-02-12       Impact factor: 21.405

6.  Expression of endothelia and lymphocyte adhesion molecules in bronchus-associated lymphoid tissue (BALT) in adult human lung.

Authors:  Nakaaki Kawamata; Baohui Xu; Hiroo Nishijima; Kohji Aoyama; Mayumi Kusumoto; Toru Takeuchi; Chuwa Tei; Sara A Michie; Takami Matsuyama
Journal:  Respir Res       Date:  2009-10-22

7.  Bronchus-associated lymphoid tissue (BALT) and survival in a vaccine mouse model of tularemia.

Authors:  Damiana Chiavolini; Javier Rangel-Moreno; Gretchen Berg; Kate Christian; Laura Oliveira-Nascimento; Susan Weir; Joseph Alroy; Troy D Randall; Lee M Wetzler
Journal:  PLoS One       Date:  2010-06-16       Impact factor: 3.240

8.  Controlling influenza by cytotoxic T-cells: calling for help from destroyers.

Authors:  Michael Schotsaert; Lorena Itatí Ibañez; Walter Fiers; Xavier Saelens
Journal:  J Biomed Biotechnol       Date:  2010-05-24

9.  What is the clinical relevance of different lung compartments?

Authors:  Thomas Tschernig; Reinhard Pabst
Journal:  BMC Pulm Med       Date:  2009-08-11       Impact factor: 3.317

10.  Induced bronchus-associated lymphoid tissue serves as a general priming site for T cells and is maintained by dendritic cells.

Authors:  Stephan Halle; Hélène C Dujardin; Nadja Bakocevic; Henrike Fleige; Heike Danzer; Stefanie Willenzon; Yasemin Suezer; Günter Hämmerling; Natalio Garbi; Gerd Sutter; Tim Worbs; Reinhold Förster
Journal:  J Exp Med       Date:  2009-11-16       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.